TD Asset Management
OVID icon

TD Asset Management’s Ovid Therapeutics OVID Stock Holding History

TD Asset Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-13,580
Closed -$96K – 1436
2018
Q1 		$96K Hold
13,580
– – ﹤0.01% 1334
2017
Q4 		$134K Buy
+13,580
New +$125K ﹤0.01% 1317

Other funds holding OVID

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TD Asset Management's OVID Position: Q2 2018 in Review

TD Asset Management sold out of Ovid Therapeutics (OVID) in Q2 2018, closing a stake of 13,580 shares — an estimated $96K sold.

TD Asset Management first reported a position in OVID in Q4 2017 and held it in 2 quarters. The position peaked at $134K in Q4 2017. 48 funds tracked by Wall St. Rank hold OVID as of Q2 2018.

  • TD Asset Management reported no remaining Ovid Therapeutics position as of Q2 2018 after selling out during the quarter.
  • TD Asset Management sold 13,580 Ovid Therapeutics shares in Q2 2018, an estimated $96K.
  • TD Asset Management first reported a position in Ovid Therapeutics in Q4 2017 and held it in 2 quarters.
  • TD Asset Management's Ovid Therapeutics position peaked at $134K in Q4 2017.
  • 48 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2018.

Based on TD Asset Management's 13F filing for Q2 2018, filed 31 Jul 2018.